Baylor Opens New Immunotherapy Clinical Trial for Mesothelioma

The Baylor College of Medicine in Houston has opened its latest clinical trial for mesothelioma patients to study the effectiveness of a novel immunotherapy combination. The nonsurgical, single-center study is looking for a dozen patients whose pleural mesothelioma has progressed after at least one regimen of chemotherapy. The phase II clinical trial involves Opdivo (nivolumab) and MTG201, a modified adenovirus designed to increase the efficacy of certain types of immunotherapy drugs. The combination was especially effective in preclinical mouse models. “We’re excited about the prospects of this combination,” thoracic surgeon and principal investigator Dr. Bryan Burt told The Mesothelioma Center at Asbestos.com. “You don’t know what the results will be until you try it, but in preclinical studies, there was a very striking response.” The impressive preclinical data is expected to be published later this summer. Burt is part of the Mesothelioma Treatment Program and the Dan L. Duncan Comprehensive Cancer Center at Baylor. He worked alongside legendary mesothelioma specialist Dr. David Sugarbaker, who helped build the Lung Institute before his death in 2018. As a surgeon, Burt understands the lack of effective treatment options available today for patients not eligible for surgery. “I don’t think anyone would argue that the survival benefits, the benefit of systemic therapy for mesothelioma patients, is suboptimal,” Burt said. “Progress in advancing long-ter...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Source Type: news